Healthy Volunteers

Researchers are working to create risk prediction models that help identify patients with a high risk of developing serious cardiovascular problems. The study focuses on individuals with structural, rhythm-related, or inflammatory cardiovascular diseases and aims to improve early detection of those at risk. This observational study is sponsored by the Medical University Innsbruck and includes adults 18 years and older. Participants in this study have their clinical data and risk factors recorded to better understand their cardiovascular condition. There are no specific treatments or interventions given as part of the study since it is observational. The study will follow patients for up to four years to observe outcomes related to cardiovascular events and hospitalizations. During the study, researchers will monitor events such as cardiovascular mortality, stroke, heart attacks, hospital stays due to heart failure, and other severe heart-related conditions. Participants will be assessed regularly through clinical data collection without additional procedures or treatments. The study aims to gather detailed information over time to improve risk assessment and patient care for cardiovascular diseases.

Researchers are evaluating the One All curriculum, which uses the sport Ultimate Frisbee to improve mental health resilience among young tribal people in two communities in South India. The study aims to see if this intervention is feasible and acceptable while assessing its effectiveness in building resilience and mental well-being. The research involves young tribal adults aged 12 to 25 years from Gudalur in Tamil Nadu and BR Hills in Karnataka. The intervention includes a three-year curriculum delivered by trained community facilitators who adapt the program to fit local needs. Participants attend two or more sessions each week, each lasting about one and a half hours. Sessions involve warm-up activities, drills, ultimate frisbee games with modified rules, and group discussions called spirit circles. The program focuses on developing skills such as self-management, social awareness, empathy, identity building, and conflict resolution. Participants undergo assessments before the program starts, after 12 months, and after 18 months. These include questionnaires measuring resilience Child Youth Resilience Measure and Connor-Davidson Resilience Scale, mental health GHQ12, and self-efficacy. Researchers will track attendance and reflections from sessions but will not access medical records. The study involves a baseline interview collecting socioeconomic data and assigns participants codes to protect privacy. Total participation lasts at least 18 months to evaluate outcomes.

Researchers are evaluating the effects of the traditional Vietnamese Xuong tan lac than exercise on joint range of motion and muscle endurance in healthy adults. This study aims to determine if practicing this exercise improves movement and muscle endurance around multiple joints including the cervical spine, lumbar spine, shoulders, elbows, wrists, knees, and ankles. The study focuses on healthy volunteers and explores how this traditional exercise may support musculoskeletal function. Participants will be trained to correctly perform the Xuong tan lac than exercise, which involves a series of breathing and controlled lateral trunk movements while standing in a semi-squat position. They will practice the exercise once daily, five days a week, for 12 weeks, following a standardized protocol. Assessments will be conducted at the start and after 2, 4, 8, and 12 weeks to track changes. Throughout the study, participants will undergo measurements of joint range of motion using the Noraxon MyoMotion system with inertial measurement sensors, as well as tests of muscle endurance. Researchers will assess nerve conduction parameters at the beginning and end of the study. These evaluations aim to capture improvements in joint mobility and muscle function over the 12-week exercise program. The study involves regular monitoring and adherence to the exercise schedule under research supervision.

The 100-Year Human Aging Study is a long-term observational research project enrolling adult participants to undergo detailed multi-system health screenings and follow them throughout their lives until death. The study aims to identify which health measurements taken at enrollment and repeatedly over time can predict overall mortality, cause-specific death, serious diseases, and functional disability. It addresses the current lack of validated longevity measures by generating data on how various physiological and cognitive functions relate to aging outcomes. Participants undergo a comprehensive clinical screening that includes tests of cardiorespiratory fitness, strength, mobility, neurocognitive performance, sensory functions, and metabolic health. Structural imaging assessments like DEXA scans, echocardiography, electrocardiography, spirometry, retinal photography, and vascular ultrasound are performed. Laboratory tests and detailed medical, social, and environmental histories are also collected. The study allows participation from single tests up to a full two-visit screening, with repeat testing encouraged to track health changes over time. Throughout the study, participants receive individualized reports with investigational estimates of biological age and predicted mortality risks, which are being evaluated against actual health outcomes. Researchers collect data continuously on mortality, disease occurrence, disability, and health behavior changes. The study involves ongoing follow-up with periodic assessments and aims to preserve all collected data for future analyses, with participant involvement potentially spanning their entire lifespan.

Researchers are developing advanced four-dimensional magnetic resonance imaging 4D-MRI techniques to create detailed, moving images of the lungs and liver in adults. This imaging method produces three-dimensional movies that capture organ motion during breathing, which is important for improving radiation therapy planning for lung and liver cancer patients. The study aims to overcome challenges in current imaging methods to better target tumors that move with respiration. The study includes two main parts technical development of ultra-quality 4D-MRI in healthy volunteers and evaluation of the technique in cancer patients. This involves creating a new MRI pulse sequence and image reconstruction process to achieve high spatial and temporal resolution with minimal motion artifacts. Researchers will compare the new 4D-MRI method to existing imaging and registration techniques in both healthy volunteers and patients with lung or liver tumors undergoing radiation therapy. Participants will undergo a single imaging session lasting up to two hours involving 4D-MRI scans. Healthy volunteers and cancer patients will be assessed to measure image quality and accuracy of motion modeling. The study will monitor how well the 4D-MRI technique captures tumor movement compared to current methods. The total participation time is limited to the imaging session, with no long-term follow-up mentioned.

Researchers are evaluating the use of 18FFT8, a diagnostic imaging agent, for detecting amyloidosis, including cardiac amyloidosis. This study aims to assess the safety and effectiveness of 18FFT8 PETCT scans in visualizing AL amyloid deposits in the heart, comparing its performance to established clinical methods such as echocardiography, MRI, and laboratory tests. The goal is to establish a reliable PET imaging protocol for direct diagnosis and differentiation of AL amyloidosis. Participants will receive a single intravenous injection of 10 b1 3 mCi of 18FFT8, followed by a PETCT scan to measure organ uptake using the standardized uptake value SUV. The study includes both healthy volunteers and amyloidosis patients. The imaging and injection occur only once, and no additional treatments are administered. Clinical assessments and lab tests are done before and after the scan to monitor safety and gather diagnostic information. During the study, participants will undergo physical exams, cardiac function assessments, and tests of liver and kidney function before and after the PETCT scan. Researchers will monitor safety from the time of injection up to seven days afterward, and evaluate organ uptake and biodistribution of 18FFT8 at the time of the scan. Radiation exposure is also measured. Total participation involves a single visit for imaging and assessments, with follow-up safety monitoring over one week.

This trial studies the pharmacokinetics of casdatifan in healthy adults aged 18 to 55 years. It compares the absorption and concentration levels of a single 100 mg dose given as one tablet versus four 25 mg tablets under fasting conditions. The study also evaluates how food intake affects the drugs pharmacokinetics when the 100 mg dose is taken as four tablets with food. Participants receive casdatifan in three different ways four 25 mg tablets while fasting, one 100 mg tablet while fasting, and four 25 mg tablets after a meal. This crossover design allows each participant to receive all treatments in a randomized order, enabling direct comparison of absorption and drug levels. During the study, participants are monitored for up to 168 hours after each dose to measure drug concentration and how the body processes casdatifan. Researchers assess the peak concentration, time to peak, elimination rate, and total exposure to the drug. Safety is monitored by recording any adverse events for up to 43 days. The entire study is conducted with healthy volunteers, and participation lasts until all dosing and follow-up assessments are complete.

Researchers are investigating the feasibility of collecting and expanding T lymphocytes from both cancer patients and healthy volunteers. The study aims to select specific immune cells marked by PD-1 and CTLA4 from the blood and assess their ability to kill tumor cells outside the body. This observational study includes adults with any stage of solid tumors, healthy volunteers, and individuals with COVID-19, with special provisions for pediatric participants aged 5 to 17 years. Participants are divided into three groups cancer patients receiving routine care, healthy volunteers who help optimize study procedures, and COVID-19 patients whose participation may be limited based on their condition. Adults and pediatric participants undergo blood and other minimally invasive biospecimen collections, including leukapheresis for eligible adults, to obtain immune and tumor cells. The study supports quality control, assay development, and device validation across cohorts. During the study, participants provide biospecimens such as blood, saliva, urine, and swabs. Researchers will analyze these samples to evaluate immune cell function and develop an ex-vivo device platform for culture, immune testing, and biobanking. The study collects clinical information and laboratory test results, including infection status and organ function markers. Participation requires informed consent and may include repeated sampling over time to support ongoing research efforts.

Researchers are evaluating how well MSP-2020, a study drug, attaches to serotonin type 2A receptors in the brain of healthy male adults. This Phase 1 study aims to understand the drugs presence in the blood, how long it stays, and its safety profile. The study is conducted by Otsuka Pharmaceutical Development & Commercialization, Inc. and focuses on healthy volunteers aged 23 to 55 years. Participants will receive a single oral dose of MSP-2020 on Day 1. The study uses positron emission tomography PET scans to measure receptor occupancy and drug binding. Blood samples will be collected up to Day 2 to analyze the drugs concentration, peak levels, half-life, and metabolite presence. Safety will be monitored through assessments including vital signs, ECG, laboratory tests, and neurological exams. During the study, participants will stay in a clinical research unit for up to 4 days for observation and assessments. Researchers will monitor adverse events and changes in health status up to Day 15. The primary outcomes focus on drug binding in the brain and pharmacokinetics, while secondary outcomes include safety measures and changes in relevant clinical scales. The total participation time includes dosing, imaging, blood sampling, and safety follow-up.

Researchers are conducting a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic profile of AK0610 in healthy Chinese adults aged 18 to 50. The study is randomized, double-blind, and placebo-controlled, focusing on single-dose administration with dose escalation and expansion phases. The trial involves healthy volunteers to understand how the body processes AK0610 and to monitor any side effects. The trial has two parts a dose-escalation phase with five cohorts receiving increasing doses of AK0610 or placebo either intramuscularly or intravenously, and an expansion phase with two additional cohorts based on pharmacokinetic data. Doses range from 100 mg to 3000 mg, administered once on Day 1. Participants receive either AK0610 or placebo in a 31 ratio in all cohorts. Participants undergo a screening period from Day -29 to Day -1, followed by the dosing on Day 1 and an inpatient observation period until Day 8. Afterward, there is a blinded follow-up period lasting until Day 181, with those receiving AK0610 entering an open-label period from Day 182 to Day 361. Researchers will monitor adverse events, measure serum drug concentrations, and assess immunogenicity and RSV-neutralizing activity throughout the study.